Achilles Therapeutics plc - ACHL Enterprise Value-to-Sales Ratio

Public company logo of Achilles Therapeutics (ACHL)

Achilles Therapeutics (ACHL) relies on the potential of the PELEUS platform and bioprinting patents. This GURU.Markets terminal chart displays the current EV/Sales ratio, where the value describes the current level. The asset is shielded from macroeconomic volatility by a sovereign development cycle, although the high cost of scientific research and stringent regulatory oversight create significant barriers to rapid business scaling.

Achilles Therapeutics PLC (ACHL): Enterprise Value-to-Revenue Ratio from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Achilles Therapeutics plc (ACHL)

- money and cash flow information:
Fundamental valuation:Achilles Therapeutics PLC (ACHL)
Core merchandise of achillestx.com

A conservative investor assesses the fundamental stability of Achilles Therapeutics (ACHL) by comparing market capitalization with net debt and sales volume. Analyzing the enterprise value-to-revenue ratio helps determine the extent of the premium paid for potential in the untapped personalized immunotherapy segment, where high chart volatility signals a market reassessment of future revenues from clinical centers.